|

Study of SIR2501 in Solid Tumor Patients Receiving Paclitaxel

RECRUITINGPhase 2Sponsored by Sironax USA, Inc.
Actively Recruiting
PhasePhase 2
SponsorSironax USA, Inc.
Started2026-08-21
Est. completion2027-12-31
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations2 sites
View on ClinicalTrials.gov →

NCT07765446

Summary

This Phase 2, open-label study will evaluate the safety, tolerability, and pharmacokinetics of SIR2501 in adults with solid tumors who are scheduled to receive paclitaxel-based chemotherapy. The study will also explore whether SIR2501 has the potential to reduce the development of chemotherapy-induced peripheral neuropathy (CIPN).

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Adults ≥18 years with confirmed solid tumors
* Planned treatment with paclitaxel-based chemotherapy
* ECOG performance status 0-2

Exclusion Criteria:

* Pre-existing peripheral neuropathy
* Conditions or medications that may interfere with neuropathy assessment
* Prior exposure to neurotoxic chemotherapy
* Use of medications known to mitigate CIPN
* Significant medical conditions that may increase study risk

Conditions2

CancerChemotherapy-induced Peripheral Neuropathy

Interventions1

SIR2501

Locations2 sites

Maryland

1 site
Baltimore, Maryland, 21287

New Jersey

1 site
East Brunswick, New Jersey, 08816

Find trials near these locations

Cancer trials in BaltimoreAll trials in Maryland

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.